Drug Trial News

RSS

Targets against MRSA in microgravity

NASA astronauts onboard Space Shuttle Discovery's final mission to the International Space Station (ISS) will carry out the eleventh scientific payload for Astrogenetix, a commercial biotech company based out of Austin, Texas. The research on STS-133 will focus on changes that occur to methicillin-resistant Staphylococcus aureus (MRSA) in microgravity, which can be targeted to create new vaccines and therapeutics.

25 Feb 2011

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Protalix BioTherapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease. Taliglucerase alfa is a plant-cell expressed form of glucocerebrosidase (GCD).

25 Feb 2011

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of the first reported case in which adenovirus infection was successfully eradicated following treatment with its broad-spectrum antiviral drug, CMX001.

25 Feb 2011

Radioactive tracing agent can identify tumor-draining sentinel nodes in breast cancer, melanoma patients

Researchers say a new kind of tracing agent is more accurate than current methods in helping identify tumor-draining sentinel lymph nodes in breast cancer and melanoma patients. That's the finding in a new study that appears in the online version of the Annals of Surgical Oncology.

25 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Enobia completes patient enrollment in ENB-0040 Phase II study for HPP

Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.

25 Feb 2011

Lux initiates pivotal voclosporin Phase 3 trial in non-infectious uveitis

Isotechnika Pharma Inc. announced today that Lux Biosciences, Inc. has commenced its pivotal Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability.

25 Feb 2011

Zoledronic acid demonstrates anti-angiogenic effects in metastatic lung cancer

A drug that is currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier stage of treatment, to prevent the cancer from spreading in the first place, Italian researchers have found.

25 Feb 2011

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs.

25 Feb 2011

BioCryst receives HHS contract to complete peramivir Phase 3 study in patients with influenza

BioCryst Pharmaceuticals, Inc. announced that it has been awarded a $55.0 million contract modification by the U.S. Department of Health & Human Services intended to fund to completion the Phase 3 development of its neuraminidase inhibitor, intravenous peramivir, for the treatment of patients hospitalized with influenza.

25 Feb 2011

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, today announced the successful completion of a Phase 1 exposure-escalation clinical study with its synthetic defensin-mimetic antibiotic, PMX-30063.

24 Feb 2011

BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD

BioSante Pharmaceuticals, Inc. today announced that enrollment of subjects in the first of two pivotal Phase III LibiGel safety and efficacy trials has been completed.

24 Feb 2011

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Isis Pharmaceuticals, Inc. announced today the results from a Phase 1 clinical trial in which ISIS-CRPRx produced statistically significant reductions in C-reactive protein in the cohort of subjects in the study with elevated CRP.

24 Feb 2011

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.

24 Feb 2011

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

Vertex Pharmaceuticals Incorporated today announced positive results from the Phase 3 STRIVE study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

24 Feb 2011

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

24 Feb 2011

Oncolytics completes patient enrollment in REOLYSIN trial to treat metastatic colorectal cancer

Oncolytics Biotech Inc. announced today that enrollment has been completed in a U.K. translational clinical trial investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases.

23 Feb 2011

PCI Biotech completes patient inclusion in PC-A11 phase I/II study to treat cancer

PCI Biotech the Norwegian biopharmaceutical company, reported today that it has completed the inclusion of patients in its phase I/II study of its lead candidate PC-A11 in cancer patients.

23 Feb 2011

Trevena commences TRV120027 Phase 2a trial in patients with acute heart failure

Trevena Inc., the leader in G-protein coupled receptor biased ligand drug discovery, today announced the initiation of a Phase 2a clinical trial with its lead program, TRV120027, a beta-arrestin biased angiotensin II type 1 receptor ligand, the first biased ligand designed to treat patients with acute heart failure.

23 Feb 2011

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

Aestus Therapeutics, Inc., announced today that it has initiated screening of patients for a clinical trial to evaluate the efficacy of its novel pain therapeutic, ATx08-001. This placebo-controlled, two-dose level study will test the efficacy of ATx08-001 in reducing the pain following an outbreak of shingles.

23 Feb 2011

Drug Trial News

Targets against MRSA in microgravity

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Radioactive tracing agent can identify tumor-draining sentinel nodes in breast cancer, melanoma patients

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Enobia completes patient enrollment in ENB-0040 Phase II study for HPP

Lux initiates pivotal voclosporin Phase 3 trial in non-infectious uveitis

Zoledronic acid demonstrates anti-angiogenic effects in metastatic lung cancer

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

BioCryst receives HHS contract to complete peramivir Phase 3 study in patients with influenza

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

Oncolytics completes patient enrollment in REOLYSIN trial to treat metastatic colorectal cancer

PCI Biotech completes patient inclusion in PC-A11 phase I/II study to treat cancer

Trevena commences TRV120027 Phase 2a trial in patients with acute heart failure

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News